<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02894840</url>
  </required_header>
  <id_info>
    <org_study_id>GPO Tri Fluvac Vaccine</org_study_id>
    <nct_id>NCT02894840</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults</brief_title>
  <official_title>A Phase I/II Randomized Double Blind Controlled Study to Evaluate the Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Split Virion Influenza Vaccine in Healthy Thai Adults Aged Between 18 Years to 49 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Government Pharmaceutical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aim to evaluate the safety and immunogenicity of one dose (15 μg HA per strain
      per dose) of the GPO seasonal trivalent inactivated split virion influenza vaccine (Tri
      Fluvac) in healthy adults aged 18 to 49 years over 90 days post-injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blind randomized study consisting of two phases - Phase I and Phase II. The
      same vaccine, a seasonal trivalent inactivated split virion influenza vaccine
      [A/California/7/2009, reassortant virus NYMC X-181 (H1N1), A/Victoria/210/2009, reassortant
      virus NYMC X-187 (H3N2), and B/Brisbane/60/2008, reassortant virus NYMC BX-35 virus strains]
      will be given in both Phase I and Phase II of the study.

      The vaccine will be administered via the intramuscular route; the preferred injection site
      will be the deltoid of the non-dominant arm. After vaccination volunteers will remain at the
      clinic for at least 30 minutes to observe for any reactogenicity after immunization. Total
      follow-up is 90 days.

      Blood specimens will be collected on Day 0 prior to vaccination, Day 21, Day 60, and day 90.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>90 days</time_frame>
    <description>All Adverse Events during 90 days will be analysed in terms of percentage and relationship to study vaccine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number (Percentage) of Participants With Achieving Seroconversions or Significant Increase in Antihemagglutinin Antibody Titer.</measure>
    <time_frame>90 days</time_frame>
    <description>Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (&lt;1:10), attainment of a post-immunization titer of ≥1:40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean of Immune Response at Every Time of Assessment</measure>
    <time_frame>90 days</time_frame>
    <description>The analysis was performed only as intention-to-treat (ITT). The antibody titer values were transformed into log10 titers for calculation of the GMT at every time of assessment (Days 0,21, 60 and 90)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean of Immune Response Increase &gt; 2.5 From Baseline of H1N1,H3N2 and B/Brisbane/60/2008 Antibody Titer</measure>
    <time_frame>90 days</time_frame>
    <description>The analysis was performed only as intention-to-treat (ITT). The antibody titer values were transformed into log10 titers for calculation of the GMT at every time of assessment (Days 0, 21, 60 and 90). Proportion of increased in GMT Titer &gt; 2.5 at each time of assessment compared with baseline (Day 0) was reported both phase I and phase II</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">340</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>an inactivated influenza vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 volunteers in phase I study and 200 volunteers in phase II study will receive a single dose of a seasonal trivalent inactivated split virion influenza vaccine [A/California/7/2009, reassortant virus NYMC X-181 (H1N1), A/Victoria/210/2009, reassortant virus NYMC X-187 (H3N2), and B/Brisbane/60/2008, reassortant virus NYMC BX-35 virus strains] will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 volunteers in phase I study and 100 volunteers in phase II study will receive a single dose of placebo will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>an inactivated influenza vaccine</intervention_name>
    <description>The vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.</description>
    <arm_group_label>an inactivated influenza vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy

          -  Age 18-49 years old

          -  Having Thai ID card or equivalent

          -  All hematology, biochemistry and urine analysis are within normal range or of no
             clinical significance (not higher than 1.5 time of normal value without any clinical
             finding from history and physical examination)

          -  Able to read and write and sign written informed consent form or assent form.

        Exclusion Criteria:

          -  Known history of egg allergy

          -  Having had recently influenza infection confirmed as H1N1, H3N2, or Flu B within 3
             months preceding enrolment to the trial

          -  Vaccination against influenza in the past 6 months preceding enrolment to the trial

          -  History of bronchial asthma, chronic lung diseases, chronic rhinitis

          -  History of immunodeficiency state

          -  History of immunosuppression &lt; 6 months prior to immunization

          -  History of anaphylactic or other allergic reactions to influenza vaccine or any
             vaccine component or excipient (e.g. gentamicin or thimerosal)

          -  Acute infectious with fever &gt; 38 degree Celsius and noninfectious diseases (within 72
             hours) preceding enrollment in the trial

          -  The volunteers who have been taking immunoglobulin products or have had a blood
             transfusion during past 3 months before the beginning of the experiment

          -  Participation in other research study

          -  Pregnancy or plan to become pregnant for 60 days after enrollment or breast feeding

          -  Current alcohol abuse or drug addiction that might interfere with the ability to
             comply with trial procedures

          -  Any condition that in the opinion of the investigator would pose a health risk to the
             subject if enrolled, or could interfere with the evaluation of the vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Punnee Pitisuttithum, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 24, 2016</study_first_submitted>
  <study_first_submitted_qc>September 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2016</study_first_posted>
  <results_first_submitted>March 21, 2018</results_first_submitted>
  <results_first_submitted_qc>August 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 19, 2018</results_first_posted>
  <last_update_submitted>March 8, 2020</last_update_submitted>
  <last_update_submitted_qc>March 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Punnee Pitisuttithum</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>GPO Tri Fluvac Vaccine</keyword>
  <keyword>Tri Fluvac Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 340 participants (40 in phase I and 300 in phase II) who met all inclusion criteria and not of the exclusion criteria were enrolled in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Inactivated Influenza Vaccine Phase I</title>
          <description>A single dose of a seasonal trivalent inactivated split virion influenza vaccine [A/California/7/2009, reassortant virus NYMC X-181 (H1N1), A/Victoria/210/2009, reassortant virus NYMC X-187 (H3N2), and B/Brisbane/60/2008, reassortant virus NYMC BX-35 virus strains] 0.5 ml. was administered via the intramuscular route to the subjects at day 0 after blood collection for immunology assays.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Phase I</title>
          <description>A single dose of placebo (0.9% normal saline solution) 0.5 ml. was administered via the intramuscular route to the subjects at day 0 after blood collection for immunology assays.</description>
        </group>
        <group group_id="P3">
          <title>Inactivated Influenza Vaccine Phase II</title>
          <description>A single dose of a seasonal trivalent inactivated split virion influenza vaccine [A/California/7/2009, reassortant virus NYMC X-181 (H1N1), A/Victoria/210/2009, reassortant virus NYMC X-187 (H3N2), and B/Brisbane/60/2008, reassortant virus NYMC BX-35 virus strains] 0.5 ml. was administered via the intramuscular route to the subjects at day 0 after blood collection for immunology assays.</description>
        </group>
        <group group_id="P4">
          <title>Placebo Phase II</title>
          <description>A single dose of placebo (0.9% normal saline solution) was administered via the intramuscular route to the subjects at day 0 after blood collection for immunology assays.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="200"/>
                <participants group_id="P4" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="197"/>
                <participants group_id="P4" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inactivated Influenza Vaccine Phase I</title>
          <description>A single dose of a seasonal trivalent inactivated split virion influenza vaccine [A/California/7/2009, reassortant virus NYMC X-181 (H1N1), A/Victoria/210/2009, reassortant virus NYMC X-187 (H3N2), and B/Brisbane/60/2008, reassortant virus NYMC BX-35 virus strains] 0.5 ml. was administered via the intramuscular route to the subjects at day 0 after blood collection for immunology assays.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Phase I</title>
          <description>A single dose of placebo (0.9% normal saline solution) 0.5 ml. was administered via the intramuscular route to the subjects at day 0 after blood collection for immunology assays.</description>
        </group>
        <group group_id="B3">
          <title>Inactivated Influenza Vaccine Phase II</title>
          <description>A single dose of a seasonal trivalent inactivated split virion influenza vaccine [A/California/7/2009, reassortant virus NYMC X-181 (H1N1), A/Victoria/210/2009, reassortant virus NYMC X-187 (H3N2), and B/Brisbane/60/2008, reassortant virus NYMC BX-35 virus strains] 0.5 ml. was administered via the intramuscular route to the subjects at day 0 after blood collection for immunology assays.</description>
        </group>
        <group group_id="B4">
          <title>Placebo Phase II</title>
          <description>A single dose of placebo (0.9% normal saline solution) 0.5 ml. was administered via the intramuscular route to the subjects at day 0 after blood collection for immunology assays.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="200"/>
            <count group_id="B4" value="100"/>
            <count group_id="B5" value="340"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="200"/>
                    <measurement group_id="B4" value="100"/>
                    <measurement group_id="B5" value="340"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>Phase I and phase II was analyzed separately Phase I=40 (20 received vaccine, 20 received placebo).Phase II=300(ITT analysis). 200 received vaccine,100 received placebo).</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.25" spread="9.45"/>
                    <measurement group_id="B2" value="28.15" spread="6.72"/>
                    <measurement group_id="B3" value="32.28" spread="8.19"/>
                    <measurement group_id="B4" value="32.2" spread="7.96"/>
                    <measurement group_id="B5" value="31.22" spread="8.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Phase I and phase II was analyzed separately. Numbers in phase I = 40, Phase II = 300 (Intent to treat analysis).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="192"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Phase I: N=40 participants, Phase II: N = 300 participants</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="200"/>
                    <measurement group_id="B4" value="100"/>
                    <measurement group_id="B5" value="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>All Adverse Events during 90 days will be analysed in terms of percentage and relationship to study vaccine</description>
        <time_frame>90 days</time_frame>
        <population>All participants who receive at least one vaccination would be included in the safety population. The analysis will be conducted based on intent-to-treat (ITT) analysis. The population for the ITT analysis is defined as all individuals in the trial. The ITT analysis would include individuals who may not complete follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Inactivated Influenza Vaccine Phase I</title>
            <description>Number of Participants With Adverse Events Phase I: AE/SAE Vaccine group (N=20)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Phase I</title>
            <description>Number of Participants With Adverse Events Phase I: AE/SAE Placebo group (N = 20)</description>
          </group>
          <group group_id="O3">
            <title>Inactivated Influenza Vaccine Phase II</title>
            <description>Number of Participants With Adverse Events Phase II: AE/SAE Vaccine group (N=200)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Phase II</title>
            <description>Number of Participants With Adverse Events Phase II: AE/SAE placebo group (N=100)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>All Adverse Events during 90 days will be analysed in terms of percentage and relationship to study vaccine</description>
          <population>All participants who receive at least one vaccination would be included in the safety population. The analysis will be conducted based on intent-to-treat (ITT) analysis. The population for the ITT analysis is defined as all individuals in the trial. The ITT analysis would include individuals who may not complete follow-up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="200"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number (Percentage) of Participants With Achieving Seroconversions or Significant Increase in Antihemagglutinin Antibody Titer.</title>
        <description>Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (&lt;1:10), attainment of a post-immunization titer of ≥1:40.</description>
        <time_frame>90 days</time_frame>
        <population>Seroconversion against the hemagglutinin antigens contained in the vaccine were assessed in all studied participants both phase I and phase II. The analysis was performed as intention-to-treat (ITT).</population>
        <group_list>
          <group group_id="O1">
            <title>Inactivated Influenza Vaccine Phase I</title>
            <description>A single dose of a seasonal trivalent inactivated split virion influenza vaccine [A/California/7/2009, reassortant virus NYMC X-181 (H1N1), A/Victoria/210/2009, reassortant virus NYMC X-187 (H3N2), and B/Brisbane/60/2008, reassortant virus NYMC BX-35 virus strains] 0.5 ml. was administered via the intramuscular route to the subjects at day 0 after blood collection for immunology assays.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Phase I</title>
            <description>A single dose of placebo (0.9% normal saline solution) 0.5 ml. was administered via the intramuscular route to the subjects at day 0 after blood collection for immunology assays.</description>
          </group>
          <group group_id="O3">
            <title>Inactivated Influenza Vaccine Phase II</title>
            <description>A single dose of a seasonal trivalent inactivated split virion influenza vaccine [A/California/7/2009, reassortant virus NYMC X-181 (H1N1), A/Victoria/210/2009, reassortant virus NYMC X-187 (H3N2), and B/Brisbane/60/2008, reassortant virus NYMC BX-35 virus strains] 0.5 ml. was administered via the intramuscular route to the subjects at day 0 after blood collection for immunology assays.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Phase II</title>
            <description>A single dose of placebo (0.9% normal saline solution) 0.5 ml. was administered via the intramuscular route to the subjects at day 0 after blood collection for immunology assays.</description>
          </group>
        </group_list>
        <measure>
          <title>Number (Percentage) of Participants With Achieving Seroconversions or Significant Increase in Antihemagglutinin Antibody Titer.</title>
          <description>Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (&lt;1:10), attainment of a post-immunization titer of ≥1:40.</description>
          <population>Seroconversion against the hemagglutinin antigens contained in the vaccine were assessed in all studied participants both phase I and phase II. The analysis was performed as intention-to-treat (ITT).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="200"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="176"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="166"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="163"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="107"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="173"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008 Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="153"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008 Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="146"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean of Immune Response at Every Time of Assessment</title>
        <description>The analysis was performed only as intention-to-treat (ITT). The antibody titer values were transformed into log10 titers for calculation of the GMT at every time of assessment (Days 0,21, 60 and 90)</description>
        <time_frame>90 days</time_frame>
        <population>The antibody titer values were transformed into log10 titers for calculation of the GMT at every time of assessment (Days 0,21, 60 and 90) were assessed in all studied participants both phase I and phase II. The analysis was performed as intention-to-treat (ITT).</population>
        <group_list>
          <group group_id="O1">
            <title>Inactivated Influenza Vaccine Phase I</title>
            <description>A single dose of a seasonal trivalent inactivated split virion influenza vaccine [A/California/7/2009, reassortant virus NYMC X-181 (H1N1), A/Victoria/210/2009, reassortant virus NYMC X-187 (H3N2), and B/Brisbane/60/2008, reassortant virus NYMC BX-35 virus strains] 0.5 ml. was administered via the intramuscular route to the subjects at day 0 after blood collection for immunology assays.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Phase I</title>
            <description>A single dose of placebo (0.9% normal saline solution) 0.5 ml. was administered via the intramuscular route to the subjects at day 0 after blood collection for immunology assays.</description>
          </group>
          <group group_id="O3">
            <title>Inactivated Influenza Vaccine Phase II</title>
            <description>A single dose of a seasonal trivalent inactivated split virion influenza vaccine [A/California/7/2009, reassortant virus NYMC X-181 (H1N1), A/Victoria/210/2009, reassortant virus NYMC X-187 (H3N2), and B/Brisbane/60/2008, reassortant virus NYMC BX-35 virus strains] 0.5 ml. was administered via the intramuscular route to the subjects at day 0 after blood collection for immunology assays.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Phase II</title>
            <description>A single dose of placebo (0.9% normal saline solution) was administered via the intramuscular route to the subjects at day 0 after blood collection for immunology assays.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Immune Response at Every Time of Assessment</title>
          <description>The analysis was performed only as intention-to-treat (ITT). The antibody titer values were transformed into log10 titers for calculation of the GMT at every time of assessment (Days 0,21, 60 and 90)</description>
          <population>The antibody titer values were transformed into log10 titers for calculation of the GMT at every time of assessment (Days 0,21, 60 and 90) were assessed in all studied participants both phase I and phase II. The analysis was performed as intention-to-treat (ITT).</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="200"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.44" lower_limit="11.12" upper_limit="41.33"/>
                    <measurement group_id="O2" value="24.62" lower_limit="14.09" upper_limit="43.02"/>
                    <measurement group_id="O3" value="19.39" lower_limit="16.40" upper_limit="22.92"/>
                    <measurement group_id="O4" value="20.14" lower_limit="15.90" upper_limit="25.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380.55" lower_limit="246.97" upper_limit="586.38"/>
                    <measurement group_id="O2" value="24.62" lower_limit="14.09" upper_limit="43.02"/>
                    <measurement group_id="O3" value="392.60" lower_limit="337.59" upper_limit="456.59"/>
                    <measurement group_id="O4" value="20.00" lower_limit="15.79" upper_limit="25.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226.27" lower_limit="149.51" upper_limit="342.45"/>
                    <measurement group_id="O2" value="24.62" lower_limit="14.09" upper_limit="43.02"/>
                    <measurement group_id="O3" value="253.10" lower_limit="218.31" upper_limit="293.42"/>
                    <measurement group_id="O4" value="20.00" lower_limit="15.82" upper_limit="25.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.55" lower_limit="133.78" upper_limit="318.90"/>
                    <measurement group_id="O2" value="24.62" lower_limit="14.09" upper_limit="43.02"/>
                    <measurement group_id="O3" value="221.21" lower_limit="189.48" upper_limit="258.25"/>
                    <measurement group_id="O4" value="20.85" lower_limit="16.45" upper_limit="26.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.77" lower_limit="40.53" upper_limit="97.21"/>
                    <measurement group_id="O2" value="64.98" lower_limit="40.54" upper_limit="104.16"/>
                    <measurement group_id="O3" value="51.16" lower_limit="43.43" upper_limit="60.27"/>
                    <measurement group_id="O4" value="44.38" lower_limit="35.03" upper_limit="56.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.53" lower_limit="128.84" upper_limit="244.61"/>
                    <measurement group_id="O2" value="72.10" lower_limit="43.87" upper_limit="118.49"/>
                    <measurement group_id="O3" value="214.81" lower_limit="183.77" upper_limit="251.09"/>
                    <measurement group_id="O4" value="43.17" lower_limit="34.20" upper_limit="54.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.29" lower_limit="109.06" upper_limit="204.35"/>
                    <measurement group_id="O2" value="72.10" lower_limit="43.87" upper_limit="118.49"/>
                    <measurement group_id="O3" value="165.12" lower_limit="143.17" upper_limit="190.43"/>
                    <measurement group_id="O4" value="43.17" lower_limit="34.20" upper_limit="54.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.74" lower_limit="111.03" upper_limit="199.26"/>
                    <measurement group_id="O2" value="69.64" lower_limit="43.19" upper_limit="112.29"/>
                    <measurement group_id="O3" value="155.06" lower_limit="135.47" upper_limit="177.48"/>
                    <measurement group_id="O4" value="45.00" lower_limit="35.77" upper_limit="56.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.01" lower_limit="6.54" upper_limit="12.42"/>
                    <measurement group_id="O2" value="14.14" lower_limit="9.34" upper_limit="21.40"/>
                    <measurement group_id="O3" value="9.97" lower_limit="8.72" upper_limit="11.39"/>
                    <measurement group_id="O4" value="9.20" lower_limit="7.77" upper_limit="10.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.27" lower_limit="110.26" upper_limit="328.35"/>
                    <measurement group_id="O2" value="13.66" lower_limit="9.03" upper_limit="20.67"/>
                    <measurement group_id="O3" value="115.92" lower_limit="97.60" upper_limit="137.66"/>
                    <measurement group_id="O4" value="9.40" lower_limit="7.83" upper_limit="11.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008 Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.54" lower_limit="79.60" upper_limit="227.43"/>
                    <measurement group_id="O2" value="16.82" lower_limit="10.28" upper_limit="27.51"/>
                    <measurement group_id="O3" value="83.72" lower_limit="70.39" upper_limit="99.58"/>
                    <measurement group_id="O4" value="9.33" lower_limit="7.82" upper_limit="11.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008 Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.11" lower_limit="61.16" upper_limit="187.58"/>
                    <measurement group_id="O2" value="15.69" lower_limit="10.13" upper_limit="24.30"/>
                    <measurement group_id="O3" value="73.33" lower_limit="61.15" upper_limit="87.94"/>
                    <measurement group_id="O4" value="9.40" lower_limit="7.89" upper_limit="11.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean of Immune Response Increase &gt; 2.5 From Baseline of H1N1,H3N2 and B/Brisbane/60/2008 Antibody Titer</title>
        <description>The analysis was performed only as intention-to-treat (ITT). The antibody titer values were transformed into log10 titers for calculation of the GMT at every time of assessment (Days 0, 21, 60 and 90). Proportion of increased in GMT Titer &gt; 2.5 at each time of assessment compared with baseline (Day 0) was reported both phase I and phase II</description>
        <time_frame>90 days</time_frame>
        <population>The antibody titer values were transformed into log10 titers for calculation of the GMT at every time of assessment (Days 0,21, 60 and 90) were assessed in all studied participants both phase I and phase II. The analysis was performed as intention-to-treat (ITT).</population>
        <group_list>
          <group group_id="O1">
            <title>Inactivated Influenza Vaccine Phase I</title>
            <description>A single dose of a seasonal trivalent inactivated split virion influenza vaccine [A/California/7/2009, reassortant virus NYMC X-181 (H1N1), A/Victoria/210/2009, reassortant virus NYMC X-187 (H3N2), and B/Brisbane/60/2008, reassortant virus NYMC BX-35 virus strains] 0.5 ml. was administered via the intramuscular route to the subjects at day 0 after blood collection for immunology assays.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Phase I</title>
            <description>A single dose of placebo (0.9% normal saline solution) 0.5 ml. was administered via the intramuscular route to the subjects at day 0 after blood collection for immunology assays.</description>
          </group>
          <group group_id="O3">
            <title>Inactivated Influenza Vaccine Phase II</title>
            <description>A single dose of a seasonal trivalent inactivated split virion influenza vaccine [A/California/7/2009, reassortant virus NYMC X-181 (H1N1), A/Victoria/210/2009, reassortant virus NYMC X-187 (H3N2), and B/Brisbane/60/2008, reassortant virus NYMC BX-35 virus strains] 0.5 ml. was administered via the intramuscular route to the subjects at day 0 after blood collection for immunology assays.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Phase II</title>
            <description>A single dose of placebo (0.9% normal saline solution) was administered via the intramuscular route to the subjects at day 0 after blood collection for immunology assays.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Immune Response Increase &gt; 2.5 From Baseline of H1N1,H3N2 and B/Brisbane/60/2008 Antibody Titer</title>
          <description>The analysis was performed only as intention-to-treat (ITT). The antibody titer values were transformed into log10 titers for calculation of the GMT at every time of assessment (Days 0, 21, 60 and 90). Proportion of increased in GMT Titer &gt; 2.5 at each time of assessment compared with baseline (Day 0) was reported both phase I and phase II</description>
          <population>The antibody titer values were transformed into log10 titers for calculation of the GMT at every time of assessment (Days 0,21, 60 and 90) were assessed in all studied participants both phase I and phase II. The analysis was performed as intention-to-treat (ITT).</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="200"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.75" lower_limit="8.18" upper_limit="38.55"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="20.25" lower_limit="16.54" upper_limit="24.79"/>
                    <measurement group_id="O4" value="0.99" lower_limit="0.97" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.56" lower_limit="5.08" upper_limit="21.95"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="13.06" lower_limit="10.82" upper_limit="15.76"/>
                    <measurement group_id="O4" value="0.99" lower_limit="0.97" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.26" lower_limit="4.40" upper_limit="19.47"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="11.45" lower_limit="9.51" upper_limit="13.80"/>
                    <measurement group_id="O4" value="1.04" lower_limit="0.96" upper_limit="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" lower_limit="1.70" upper_limit="4.71"/>
                    <measurement group_id="O2" value="1.11" lower_limit="0.89" upper_limit="1.38"/>
                    <measurement group_id="O3" value="4.20" lower_limit="3.47" upper_limit="5.07"/>
                    <measurement group_id="O4" value="0.97" lower_limit="0.94" upper_limit="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" lower_limit="1.52" upper_limit="3.71"/>
                    <measurement group_id="O2" value="1.11" lower_limit="0.89" upper_limit="1.38"/>
                    <measurement group_id="O3" value="3.19" lower_limit="2.71" upper_limit="3.75"/>
                    <measurement group_id="O4" value="0.97" lower_limit="0.92" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" lower_limit="1.43" upper_limit="3.74"/>
                    <measurement group_id="O2" value="1.07" lower_limit="0.85" upper_limit="1.35"/>
                    <measurement group_id="O3" value="3.03" lower_limit="2.60" upper_limit="3.53"/>
                    <measurement group_id="O4" value="1.01" lower_limit="0.96" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.11" lower_limit="12.97" upper_limit="34.35"/>
                    <measurement group_id="O2" value="0.97" lower_limit="0.90" upper_limit="1.04"/>
                    <measurement group_id="O3" value="11.63" lower_limit="9.68" upper_limit="13.98"/>
                    <measurement group_id="O4" value="1.02" lower_limit="0.95" upper_limit="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008 Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.93" lower_limit="9.23" upper_limit="24.15"/>
                    <measurement group_id="O2" value="1.19" lower_limit="0.92" upper_limit="1.53"/>
                    <measurement group_id="O3" value="8.40" lower_limit="6.99" upper_limit="10.10"/>
                    <measurement group_id="O4" value="1.01" lower_limit="0.95" upper_limit="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008 Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.85" lower_limit="8.23" upper_limit="20.08"/>
                    <measurement group_id="O2" value="1.11" lower_limit="0.92" upper_limit="1.34"/>
                    <measurement group_id="O3" value="7.33" lower_limit="6.08" upper_limit="8.84"/>
                    <measurement group_id="O4" value="1.02" lower_limit="0.95" upper_limit="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Inactivated Influenza Vaccine Phase I</title>
          <description>Serious Adverse Event Phase I vaccine group N= 20</description>
        </group>
        <group group_id="E2">
          <title>Placebo Phase I</title>
          <description>Serious Adverse Event Phase I placebo group N= 20</description>
        </group>
        <group group_id="E3">
          <title>Inactivated Influenza Vaccine Phase II</title>
          <description>Serious Adverse Event Phase I vaccine group N= 200</description>
        </group>
        <group group_id="E4">
          <title>Placebo Phase II</title>
          <description>Serious Adverse Event Phase I placebo group N= 100</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No limitations</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Prof.Punnee Pitisuttithum</name_or_title>
      <organization>Mahidol university</organization>
      <phone>662 6435599</phone>
      <email>punnee.pit@mahidol.ac.th</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

